Cancer cells use alterations of normal metabolic processes to sustain proliferation
indefinitely. Transcriptional and posttranscriptional control of the pyruvate dehydrogenase …

Cancer cells display an altered metabolic phenotype, characterised by increased glycolysis
and lactate production, even in the presence of sufficient oxygen-a phenomenon known as …

Upon prolonged use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in non‐small‐cell lung cancer (NSCLC), acquired drug resistance inevitably occurs …

Lung adenocarcinoma (LUAD) is one of the most prevalent and aggressive types of lung
cancer. Metabolic reprogramming plays a critical role in the development and progression of …

Blockade of the programmed cell death 1 (PD-1)/PD-1 ligand-1 (PD-L1) pathway has been
exploited therapeutically in many cancer types. Upregulation of PD-L1 in tumor cells …

Abstract Pyruvate dehydrogenase kinase 1 (PDK1) is an important metabolic enzyme which
is often overexpressed in many types of cancers, including non-small-cell lung cancers …

Ovarian cancer (OC) is the most lethal of gynecological tumors in women. Tumor
metabolism has become a new opportunity in the treatment of tumors. Pyruvate …

Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-
small cell lung cancer (NSCLC) for decades with great success in patients with EGFR …

Metabolism is reprogrammed in a variety of cancer cells to ensure their rapid proliferation.
Cancer cells prefer to utilize glycolysis to produce energy as well as to provide large …

Pyruvate dehydrogenase kinases (PDKs) are promising therapeutic targets that have
received increasing attentions in cancer metabolism. In this paper, we report the synthesis …